Clinical

Articles

Screening rates rebounded across most tumor types in late 2020; however, racial and economic disparities persisted. 

Study highlights prostate and other cancer screening trends during the pandemic

The so-called “obesity paradox” previously reported in other genitourinary malignancies has now been observed in patients with metastatic castration-resistant prostate cancer.

Obesity linked to improved survival in advanced prostate cancer

Between 40% and 50% of patients with mCRPC have loss in PTEN, which is associated with worse prognosis and reduced benefit from AR blockade.

Ipatasertib plus abiraterone improves PFS in men with mCRPC and PTEN loss

In this subgroup, adjuvant radiotherapy significantly reduced the risk of all-cause mortality versus early salvage radiation therapy.

Study identifies prostate cancer subgroup likely to benefit from adjuvant radiotherapy 

Videos

Expert urologists remark on unmet needs in prostate cancer by emphasizing the importance of reaching under-served communities, addressing patient discomfort, increasing education about liquid biopsy testing, and standardizing prostate size assessment.

Unmet Needs in the Early Detection of Prostate Cancer

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

“With 18F-DCFPyL-PET/CT, we can find metastatic disease much sooner. Therefore, 1 question that will need to be addressed is: what do we do now?” says Kenneth J. Pienta, MD.









Phase 2/3 study demonstrates value of PSMA imaging agent for prostate cancer staging 

Health care providers focus on genomic testing in heavily treated, metastatic castrate-resistant prostate cancer from the multidisciplinary approach to cancer care. 

Genetic, Genomic Testing in Heavily Treated, Metastatic Castrate-Resistant Prostate Cancer

Health care providers focus on genomic testing in newly diagnosed, high grade, high-risk prostate cancer from the multidisciplinary approach to cancer care.

Genetic, Genomic Testing in Newly Diagnosed, High-Grade, High-Risk Prostate Cancer

The approval is based on a subgroup analysis of the pivotal phase 3 PROfound trial.

Olaparib approved in China for BRCA-positive mCRPC

Key opinion leaders in urology review factors to consider when selecting screening and risk-assessment tests for the diagnosis of prostate cancer including insurance coverage, commercial availability, and patient preference.  